- GlobeNewswire•23 days agoProtalix BioTherapeutics Announces Presentation of Results from the Phase I/II Clinical Trial of PRX-102 for the Treatment of Fabry Disease at the Society for the Study of Inborn Errors of Metabolism
CARMIEL, Israel, Sept. 07, 2016-- Protalix BioTherapeutics, Inc., announced today an oral presentation highlighting the results of the phase I/II clinical trial of PRX-102 for the treatment of Fabry disease ...
- GlobeNewswire•2 months agoProtalix BioTherapeutics Announces Additional Positive Data from its Phase I/II Clinical Trial for PRX-102 for the Treatment of Fabry Disease
CARMIEL, Israel, Aug. 10, 2016-- Protalix BioTherapeutics, Inc., announced today additional positive data from its phase I/II clinical trial of PRX-102 for the treatment of Fabry disease. PRX-102 is a ...
- Associated Press•2 months ago
The Carmiel, Israel-based company said it had a loss of 11 cents per share. The drug developer posted revenue of $1.8 million in the period. In the final minutes of trading on Monday, the company's shares ...
Protalix BioTherapeutics, Inc. (PLX.TA)
Tel Aviv - Tel Aviv Delayed Price. Currency in ILS
|Bid||212.60 x 128000|
|Ask||215.20 x 209400|
|Day's Range||212.60 - 216.60|
|52wk Range||2.12 - 216.60|
|1y Target Est||N/A|
|P/E Ratio (ttm)||420.16|
|Avg Vol (3m)||81,973|
|Dividend & Yield||N/A (N/A)|